Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Health Technology Assessment and Reimbursement for Select Oncology Therapies in Major European Markets

Speaker(s)

ABSTRACT WITHDRAWN

BACKGROUND: Cancer is the second leading cause of mortality and morbidity across Europe with more than 3.7 million new cases and 1.9 million deaths per year. The age-standardized rate for all cancers in UK, Germany, and France was 340 - 350 per 100,000 in 2018. Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and ovarian cancer (OC) are the most common cancers.

OBJECTIVES: The objective of this research was to understand the recommendations, reimbursement decisions, and assessment variations across 3 EU HTA agencies among 19 therapies indicated for 3 forms of cancer.

METHODS: Secondary research was conducted to identify therapies approved for use in NSCLC, CRC, and OC in the last 10 years along with the respective treatment line. Publicly available HTA information was collected from the national authority websites of UK (NICE), Germany (G-BA), and France (HAS).

RESULTS: A total of 19 therapies were analyzed (37% recommended; 32% recommended conditionally; 26% no HTA submissions; 5% HTA ongoing). The share of positive HTA recommendations without any restrictions was 37% for UK, 16% for Germany, and 58% for France. The share of reimbursed drugs was 42% in UK, 79% in Germany, and 37% in France. The sensitivity analysis revealed that the agreement between recommendations and reimbursement status was 0.58 for UK and 0.52 for France.

CONCLUSIONS: The HTA recommendations for NSCLC, CRC, and OC drastically vary among France, UK, and Germany. It is imperative to understand each system and tailor the clinical development strategy for novel therapies to the requirement nuances in the major EU markets to achieve optimal HTA decisions.

Code

HTA26

Topic

Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes, Systems & Structure

Disease

Oncology